Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer

Hengyu Lu, Nicole Villafane, Turgut Dogruluk, Caitlin L. Grzeskowiak, Kathleen Kong, Yiu Huen Tsang, Oksana Zagorodna, Angeliki Pantazi, Lixing Yang, Nicholas J. Neill, Young Won Kim, Chad J. Creighton, Roel G. Verhaak, Gordon Mills, Peter J. Park, Raju Kucherlapati, Kenneth L. Scott

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oncogenic gene fusions drive many human cancers, but tools to more quickly unravel their functional contributions are needed. Here we describe methodology permitting fusion gene construction for functional evaluation. Using this strategy, we engineered the known fusion oncogenes, BCR-ABL1, EML4-ALK, and ETV6-NTRK3, as well as 20 previously uncharacterized fusion genes identified in The Cancer Genome Atlas datasets. In addition to confirming oncogenic activity of the known fusion oncogenes engineered by our construction strategy, we validated five novel fusion genes involving MET, NTRK2, and BRAF kinases that exhibited potent transforming activity and conferred sensitivity to FDA-approved kinase inhibitors. Our fusion construction strategy also enabled domain-function studies of BRAF fusion genes. Our results confirmed other reports that the transforming activity of BRAF fusions results from truncation-mediated loss of inhibitory domains within the N-terminus of the BRAF protein. BRAF mutations residing within this inhibitory region may provide a means for BRAF activation in cancer, therefore we leveraged the modular design of our fusion gene construction methodology to screen N-terminal domain mutations discovered in tumors that are wild-type at the BRAF mutation hotspot, V600. We identified an oncogenic mutation, F247L, whose expression robustly activated the MAPK pathway and sensitized cells to BRAF and MEK inhibitors. When applied broadly, these tools will facilitate rapid fusion gene construction for subsequent functional characterization and translation into personalized treatment strategies.

Original languageEnglish (US)
Pages (from-to)3502-3512
Number of pages11
JournalCancer Research
Volume77
Issue number13
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Gene Fusion
Oncogene Fusion
Neoplasms
Mutation
Proto-Oncogene Proteins B-raf
Atlases
Mitogen-Activated Protein Kinase Kinases
Phosphotransferases
Genome
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer. / Lu, Hengyu; Villafane, Nicole; Dogruluk, Turgut; Grzeskowiak, Caitlin L.; Kong, Kathleen; Tsang, Yiu Huen; Zagorodna, Oksana; Pantazi, Angeliki; Yang, Lixing; Neill, Nicholas J.; Kim, Young Won; Creighton, Chad J.; Verhaak, Roel G.; Mills, Gordon; Park, Peter J.; Kucherlapati, Raju; Scott, Kenneth L.

In: Cancer Research, Vol. 77, No. 13, 01.07.2017, p. 3502-3512.

Research output: Contribution to journalArticle

Lu, H, Villafane, N, Dogruluk, T, Grzeskowiak, CL, Kong, K, Tsang, YH, Zagorodna, O, Pantazi, A, Yang, L, Neill, NJ, Kim, YW, Creighton, CJ, Verhaak, RG, Mills, G, Park, PJ, Kucherlapati, R & Scott, KL 2017, 'Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer', Cancer Research, vol. 77, no. 13, pp. 3502-3512. https://doi.org/10.1158/0008-5472.CAN-16-2745
Lu, Hengyu ; Villafane, Nicole ; Dogruluk, Turgut ; Grzeskowiak, Caitlin L. ; Kong, Kathleen ; Tsang, Yiu Huen ; Zagorodna, Oksana ; Pantazi, Angeliki ; Yang, Lixing ; Neill, Nicholas J. ; Kim, Young Won ; Creighton, Chad J. ; Verhaak, Roel G. ; Mills, Gordon ; Park, Peter J. ; Kucherlapati, Raju ; Scott, Kenneth L. / Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer. In: Cancer Research. 2017 ; Vol. 77, No. 13. pp. 3502-3512.
@article{e0dbda99bd99437085adca3a1582b6c8,
title = "Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer",
abstract = "Oncogenic gene fusions drive many human cancers, but tools to more quickly unravel their functional contributions are needed. Here we describe methodology permitting fusion gene construction for functional evaluation. Using this strategy, we engineered the known fusion oncogenes, BCR-ABL1, EML4-ALK, and ETV6-NTRK3, as well as 20 previously uncharacterized fusion genes identified in The Cancer Genome Atlas datasets. In addition to confirming oncogenic activity of the known fusion oncogenes engineered by our construction strategy, we validated five novel fusion genes involving MET, NTRK2, and BRAF kinases that exhibited potent transforming activity and conferred sensitivity to FDA-approved kinase inhibitors. Our fusion construction strategy also enabled domain-function studies of BRAF fusion genes. Our results confirmed other reports that the transforming activity of BRAF fusions results from truncation-mediated loss of inhibitory domains within the N-terminus of the BRAF protein. BRAF mutations residing within this inhibitory region may provide a means for BRAF activation in cancer, therefore we leveraged the modular design of our fusion gene construction methodology to screen N-terminal domain mutations discovered in tumors that are wild-type at the BRAF mutation hotspot, V600. We identified an oncogenic mutation, F247L, whose expression robustly activated the MAPK pathway and sensitized cells to BRAF and MEK inhibitors. When applied broadly, these tools will facilitate rapid fusion gene construction for subsequent functional characterization and translation into personalized treatment strategies.",
author = "Hengyu Lu and Nicole Villafane and Turgut Dogruluk and Grzeskowiak, {Caitlin L.} and Kathleen Kong and Tsang, {Yiu Huen} and Oksana Zagorodna and Angeliki Pantazi and Lixing Yang and Neill, {Nicholas J.} and Kim, {Young Won} and Creighton, {Chad J.} and Verhaak, {Roel G.} and Gordon Mills and Park, {Peter J.} and Raju Kucherlapati and Scott, {Kenneth L.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-16-2745",
language = "English (US)",
volume = "77",
pages = "3502--3512",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer

AU - Lu, Hengyu

AU - Villafane, Nicole

AU - Dogruluk, Turgut

AU - Grzeskowiak, Caitlin L.

AU - Kong, Kathleen

AU - Tsang, Yiu Huen

AU - Zagorodna, Oksana

AU - Pantazi, Angeliki

AU - Yang, Lixing

AU - Neill, Nicholas J.

AU - Kim, Young Won

AU - Creighton, Chad J.

AU - Verhaak, Roel G.

AU - Mills, Gordon

AU - Park, Peter J.

AU - Kucherlapati, Raju

AU - Scott, Kenneth L.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Oncogenic gene fusions drive many human cancers, but tools to more quickly unravel their functional contributions are needed. Here we describe methodology permitting fusion gene construction for functional evaluation. Using this strategy, we engineered the known fusion oncogenes, BCR-ABL1, EML4-ALK, and ETV6-NTRK3, as well as 20 previously uncharacterized fusion genes identified in The Cancer Genome Atlas datasets. In addition to confirming oncogenic activity of the known fusion oncogenes engineered by our construction strategy, we validated five novel fusion genes involving MET, NTRK2, and BRAF kinases that exhibited potent transforming activity and conferred sensitivity to FDA-approved kinase inhibitors. Our fusion construction strategy also enabled domain-function studies of BRAF fusion genes. Our results confirmed other reports that the transforming activity of BRAF fusions results from truncation-mediated loss of inhibitory domains within the N-terminus of the BRAF protein. BRAF mutations residing within this inhibitory region may provide a means for BRAF activation in cancer, therefore we leveraged the modular design of our fusion gene construction methodology to screen N-terminal domain mutations discovered in tumors that are wild-type at the BRAF mutation hotspot, V600. We identified an oncogenic mutation, F247L, whose expression robustly activated the MAPK pathway and sensitized cells to BRAF and MEK inhibitors. When applied broadly, these tools will facilitate rapid fusion gene construction for subsequent functional characterization and translation into personalized treatment strategies.

AB - Oncogenic gene fusions drive many human cancers, but tools to more quickly unravel their functional contributions are needed. Here we describe methodology permitting fusion gene construction for functional evaluation. Using this strategy, we engineered the known fusion oncogenes, BCR-ABL1, EML4-ALK, and ETV6-NTRK3, as well as 20 previously uncharacterized fusion genes identified in The Cancer Genome Atlas datasets. In addition to confirming oncogenic activity of the known fusion oncogenes engineered by our construction strategy, we validated five novel fusion genes involving MET, NTRK2, and BRAF kinases that exhibited potent transforming activity and conferred sensitivity to FDA-approved kinase inhibitors. Our fusion construction strategy also enabled domain-function studies of BRAF fusion genes. Our results confirmed other reports that the transforming activity of BRAF fusions results from truncation-mediated loss of inhibitory domains within the N-terminus of the BRAF protein. BRAF mutations residing within this inhibitory region may provide a means for BRAF activation in cancer, therefore we leveraged the modular design of our fusion gene construction methodology to screen N-terminal domain mutations discovered in tumors that are wild-type at the BRAF mutation hotspot, V600. We identified an oncogenic mutation, F247L, whose expression robustly activated the MAPK pathway and sensitized cells to BRAF and MEK inhibitors. When applied broadly, these tools will facilitate rapid fusion gene construction for subsequent functional characterization and translation into personalized treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=85023752669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023752669&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-2745

DO - 10.1158/0008-5472.CAN-16-2745

M3 - Article

C2 - 28512244

AN - SCOPUS:85023752669

VL - 77

SP - 3502

EP - 3512

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -